Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab.

ABSTRACT: A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyloid plaques in Alzheimer's disease, in murine biological matrices. This method addresses the challenges of quantifying biotherapeutics in multiple tissue types within preclinical animal models with complex genetic backgrounds, where traditional enzyme-linked immunosorbent assay (ELISA) methods may suffer from interference and limited sensitivity. The assay uses parallel reaction monitoring on a Lumos Tribrid Orbitrap mass spectrometer, coupled with an Evosep LC system, and AssayMap Bravo-based automated sample processing. Key features include protein A enrichment for improved sensitivity, optimiz

SUBMITTER: Doud EH 

PROVIDER: S-EPMC12296118 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature